DAFTAR PUSTAKA

1. ADA. *Diagnosis and Classification of Diabetes Mellitus*. Diabetes Care Volume 37, Supplement 1, January 2014. https://doi.org/10.2337/dc14-S081

2. Dyah Purnamasari. *Diagnosis dan Klasifikasi Diabetes Melitus*. Buku Ajar Ilmu Penyakit Dalam. Jilid 1. Edisi VI. Internal Publishing : Jakarta. 2014. Hal : 2323-27.

3. Schwatrz SS, Solomon Epstein, Barbara E et al. *The time is right for a new classification system for diabetes rationale and implications of the* E-*cell-centric classification schema*. Diabetes Care 2016 Feb; 39(2): 179-186.

4. Sidarta Soegondo. *Farmakoterapi Pada Pengendalian Glikemia Diabetes Melitus Tipe 2*. Buku Ajar Ilmu Penyakit Dalam. Jilid 1. Edisi VI. Internal Publishing : Jakarta. 2014. Hal : 2328-35.

5. Alvin C.Powers *Diabetes Melitus: Diagnosis, Classification, and Pathophysiology*. Harrison's Principles Of Internal Medicine. Edisis 19. 2012. NewYork: McGrawHill Education. Hal : 2399-2407.

6. Parvaneh Baghaei, Majid Marjani, Pedram Javanmard et *al Diabetes mellitus and tuberculosis facts and controversies*. Journal of Diabetes & Metabolic Disorders 2013, 12:58.

7. INFODATIN. *Diabetes Melitus*.2000. INFODATIN.
   https://pusdatin.kemkes.go.id

8. Nageswara rao gopathi, Venu Mandava, Sravani Makala. *Tuberculosis and Diabetes : the deadly duo.* jimemdicine. 2015.ijam.
   DOI: http://dx.doi.org/10.18203/2349-3933.

9. Suhail Ahmad. *Pathogenesis, Immunology, and Diagnosis of Latent Mycobacterium tuberculosis Infection*. Clinical and Developmental Immunology. Volume 2011, Article ID 814943, 17 pages. Hindawi Publishing Corporation. doi:10.1155/2011/814943.

10. Magdalena D, Magdalena K-Kulbat, Marek Fol el al. Latent M. tuberculosis Infection-Pathogenesis, Diagnosis, Treatment and Prevention Strategies. 2012. Polish journal of microbiology 61(1):3-10. DOI: 10.33073/pjm-2012-001.

11. Ernest Yorke,1 Yacoba Atiase,1 Josephine Akpalu et al. *The Bidirectional Relationship between Tuberculosis and Diabetes*. Hindawi. 2017. https://doi.org/10.1155/2017/1702578.

12. A. D. Harries, A. M. V. Kumar, S. Satyanarayana,et al. *Diabetes mellitus and tuberculosis: programmatic management issues*. The International Journal of Tuberculosis and Lung Disease.2018.

    https://dx.doi.org/10.5588%2Fijtld.15.0069.

13. Jiyani M. R, Vadgama P. K., Pandey A. S, Modh et al. Clinical Profile and outcome of Tuberculosis in Patients with Diabetes. Int J Res Med. 2015; 4(2);36-40.

14. Yan Lin, AD Harries, AMV Kumar et al. *Management Of Diabetes Mellitus-Tuberculosis*. A Guide to the Essential Practice First Edition 2018. International Union Against Tuberculosis and Lung Disease. 1 ed. 2019: 33-57. https://www.theunion.org

15. Srujitha Marupuru, Padmanav Senapati, Swathi Pathadka et al. *Protective effect of metformin against tuberculosis infections in diabetic patients: an*

observational study of south Indian tertiary healthcare facility. braz j infect dis 2017;2 1(3):312–316.

16. Kelly B, Tannahill GM, Murphy MP, et al. Metformin inhibits the production of reactive oxygen species from NADH: Ubiquinone oxidoreductase to limit induction of interleukin-1β (IL-1β) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. *J Biol Chem*. 2015; 290 (33): 20348–20359,

17. Vashisht R and Brahmachari SK. Metformin as a potential combination therapy with existing front-line antibiotics for tuberculosis. *J Transl Med.* 2015;13 :81-83

18. Ndishimye P, Seghrouchni F, Domokos B, et al. Evaluation of interleukin-10 levels in the plasma of patients with various stage of tuberculosis. *Clujul Medical*. 2015; 88(2):164-7.

19. Restrepo B.I. *Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients. Elsevier*. 2016; 1-4.

20. Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. *Science Translational Medicine.*2014; 6:1-9

21. Pan SW, Yen YF, Kou YR, et al. The risk of tb in patients with type 2 diabetes initiating metformin vs sulfonylurea treatment. *Chest.* 2017; 1-11.

22. Ming-Chia Lee, Chen-Yuan Chiang, Chih-Hsin Lee et al.. *Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria*. PLOS ONE. 2018 .

https://doi.org/10.1371/journal.pone.0205807

23. Ye-Jin Lee, Sung Koo Han, Ju Hee Park et al. *The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus*. Korean J Intern Med 2018;33:933-940

    https://doi.org/10.3904/kjim.2017.249

24. Bernadette Dian Novita, Mulyohadi Ali, Agung et al. *Metformin induced autophagy in diabetes mellitus Tuberculosis co-infection patients: A case study*. Indian Journal of Tuberculosis 66 (2019) 64-69.

    https://doi.org/10.1016/j.ijtb.2018.04.003

25. ADA. *Standards of Medical Care in Diabetesd*. 2020. Diabetes Care 2020;43 (Suppl. 1):S1–S2. https://doi.org/10.2337/dc20-SINT.

26. PERKENI. *Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia 2019*. PB PERKENI. https://pbperkeni.or.id/wp-content/uploads/2020/07

27. Alvin C.Powers. *Diabetes Melitus: Management and Therapies*. Harrison's Principles Of Internal Medicine. Edisis 19. 2012. NewYork: Mc Graw Hill Education. Hal : 2407-17.

28. Unai Galicia-Garcia, Asier Benito-Vicente, Shifa Jebari. *Pathophysiology of Type 2 Diabetes Mellitus*. Int. J. Mol. Sci. 2020. doi:10.3390/ijms21176275.

29. Li Gong, Srijib Goswami, K.M. Giacomini et al. *Metformin pathways: pharmacokinetics and pharmacodynamics*. Pharmacogenet Genomics. 2012 November ; 22(11): 820–827..

30. Robert L. Hunter. *The Pathogenesis of Tuberculosis: The Early Infiltrate of Post-primary (Adult Pulmonary) Tuberculosis: A Distinct Disease Entity*. J Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.02108.

31. Garrett Teskey, Ruoqiong Cao, Stephen Cerni et al. *The Pathogenesis of Tuberculosis-Diabetes Comorbidity.* Medical Research Archives vol 5 Issue 12. http://journals.ke-i.org/index.php/mra.

32. Tong Zhou, Zheng Hu, Shuo Yang et al. *Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus.* Journal of Diabetes Research.2018. https://doi.org/10.1155/2018/7457269.

33. Steve Ferlita, Aram Yegiazaryan, Navid Noori et al. *Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis.* J. Clin. Med. 2019. doi:10.3390/jcm8122219.

34. Shuji Sasaki1, Toyoshi Inoguch. *The Role of Oxidative Stress in the Pathogenesis of Diabetic Vascular Complications*. Diabetes Metab J 2012;36:255-261.

35. Ahmad Nurdin, Helmia Hasan. *Pengaruh Jintan Hitam (Nigella Sativa) pada Konversi Sputum dan IFN- γ Penderita Tuberkulosis Paru yang Mendapat OAT Kategori I pada Akhir Minggu Kedua Fase Intensif.* Jurnal Respirasi (JR), Vol. 1. No. 3 September 2015: 73-80

36. Yung-Che Chena, Chien-Hung China, Shih-Feng Liua, et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis IOS Press Disease Markers.2011. DOI 10.3233/DMA-2011-0808.

37.   Andy Sulaiman Siregar, Soedarsono. *Perubahan Kadar Interleukin 17 pada Pasien TB Paru BTA Positif Setelah 2 Bulan Pengobatan Anti Tuberkulosis.* Respir Indo. 2018; 38: 219-26

38. Lichen Xu, Guangying Cui, Hongyu Jia Xu et al. *Decreased IL-17 during treatment of sputum smear-positive pulmonary tuberculosis due to increased regulatory T cells and IL-10.* J Transl Med (2016) 14:179. DOI 10.1186/s12967-016-0909-6

39.   Eliene D. D. Mesquita, Leonardo Gil-Santana, Daniela Ramalho, et al. *Associations between systemic inflammation, mycobacterial loads in sputum and radiological improvement after treatment initiation in pulmonary TB patients from Brazil: a prospective cohort study.* BMC Infectious Diseases (2016) 16:368 . DOI 10.1186/s12879-016-1736-3.

40. Doddy Febryan, Parluhutan Siagian, Ricke Loesnihari. *Interleukin Level 10 As A Biomarker ini Improved Treatment Of Pulmonary Tuberculosis Before Treatment And After 2 Months Of Anti Tuberculosis Treatment.* Thomsom Reuters : International Journal of Research Science & Management, *7(5): May, 2020*]. ISSN: 2349-5197. Impact Factor: 3.765. http: // www.ijrsm.com.

41. Xuejiao Luo, Furong Wu, Jun Ma et al. *Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment.* Journal of International Medical Research 2018, Vol. 46(9) 3539–3551.
DOI: 10.1177/0300060518773258.

42. Krzysztof Kuziemski, Krzysztof Specjalski, Ewa Jassem. *Diabetic Pulmonary Microangiopathy - fact or fiction?.* Endokrynol Pol 2011; 62 (2): 171–175.

43.   Nathella Pavan Kumar, Parakkal Jovvian George, Paul Kumaran et al., *Diminished systemicand antigen-specific type 1, type 17, and other proinflammatory cytokines in diabetic and prediabetic individuals with latent Mycobacterium tuberculosis infection.* J Infect Dis. 2014 Nov 15; 210(10): 1670–1678. doi: 10.1093/infdis/jiu329

44. Catherine Riou, Blas Perez Peixoto, Lindi Roberts et al. *Effect of Standard Tuberculosis Treatment on Plasma Cytokine Levels in Patients with Active Pulmonary Tuberculosis.* PLoS ONE 7(5): e36886.

   doi:10.1371/journal.pone.0036886.

45.   Garrett Teskey, Ruoqiong Cao, Stephen Cerni. The Pathogenesis of Tuberculosis-Diabetes Comorbidity. edical Research Archives vol 5 Issue 12.

   http://journals.ke-i.org/index.php/mra

46. Putri B. Machmud, Ratna Djuwita1, Dwi *Gayatri et al. Influence of Micronutrient Consumption by Tuberculosis Patients on the Sputum Conversion Rate: A Systematic Review and Meta-analysis Study*. Acta Med Indones. Indones J Intern Med. Vol 52 .Number 2. April 2020.

47. Alexznder.P.Marpaung, P Siagian, D.K.SariI. *Influence of Vitamin A Supplementation in Medication of Pulmonary TB Patients on Acceleration of Sputum Conversion in Intensive Phase in The Working Area of Medan Kota Sub District Puskesmas*. Jurnal Ilmu Kefarmasian Indonesia. 2018. 124-130 Vol. 16, No. 2 ISSN 1693-1831.

48. T.A Pakasi, E.Karyadi, Ni Made D.S et al. *Zinc and vitamin A supplementation fails to reduce sputum conversion time in severely malnourished pulmonary*

tuberculosis patients in Indonesia. Nutrition Journal 2010, 9:41. http://www.nutritionj.com/content/9/1/41.

49. Arbab Afzal1, Rabia Rathore, Nasir Farooq Butt et al. *Efficacy of Vitamin D supplementation in achieving an early sputum conversion in smear positive Pulmonary Tuberculosis*. Pak J Med Sci. 2018;34(4):849-854.

    doi: https://doi.org/10.12669/pjms.344.14397.

50. Matthew J. Magee, Argita D. Salindri, Nang Thu Thu Kyaw et al. *Stress Hyperglycemia in Patients with Tuberculosis Disease: Epidemiology and Clinical Implications*. Curr Diab Rep; 18(9): 71. doi:10.1007/s11892-018-1036-y.

51. David Brealey, Mervyn Singer. *Hyperglycemia in Critical Illness: A Review. Journal of Diabetes Science and Technology*. Volume 3, Issue 6, November 2009. [on line], diakses tanggal 01-01-2019.

    https://journals.sagepub.com/doi/abs/10.1177/193229680900300604

52. Farshad K, Mojtaba M, Mohammad A et al. *Mechanisms underlying stress-induced hyperglycemia in critically ill patients*. Futuremedicine. 10.2217/14750708.4.1.97. 2007. [online], diakses tanggal 17-03-2020. www.futuremedicine.com

53. Kaushik Mukherjee, Vance LA , Justin E et al. *Glycemic control in critically ill surgica patients: risks and benefits*. Dovepress. [online], diakses tanggal 17-03-2020.   http://dx.doi.org/10.2147/OAS.S50416. www.dovepress.com

54. Marina V.V, Rafael B.M, Amanda R.F et al . *Assessment and treatment of hyperglycemia in critically ill patients*. Rev Bras Ter Intensiva. 2014;26(1):71-76. [online], diakses tanggal 17-03-2020. DOI: 10.5935/0103-507X.20140011.

55. Bertram G. Katzung. *Drugs That Primarily Lower Glucose Levels by Their Actions On The Liver, Muscle and Adipose Tissue : Biguanides.* Basic and Clinical Pharmacology. 14th Edition. McGraw Hill Education : San Fransisco.2018. Hal 759-60.

56. Ekta Lachmandas , Clare Eckold , Julia Böhm et al. *Metformin Alters Human Host Responses to Mycobacterium tuberculosis in Healthy Subjects*. J Infect Dis. 2019 Jun 5;220(1):139-150. doi: 10.1093/infdis/jiz064.

57. Novita, Mandala W. *Metformin associated interleukin-10 affected insulin sensitivity and anti-tuberculosis result in type 2 diabetes with tuberculosis coinfection: a case report*. *J Clin Respir Dis Care*. 2018; 1-3.

58. Vashisht R and Brahmachari SK. *Metformin as a potential combination therapy with existing front-line antibiotics for tuberculosis*. *J Transl Med.* 2015;13 :81-83.

59. Ndishimye P, Seghrouchni F, Domokos B, et al. Evaluation of interleukin-10 levels in the plasma of patients with various stage of tuberculosis. *Clujul Medical*. 2015; 88(2):164-7.

60. N.R Puetri, Z.Hadifah, A. Nur et al . *Comparison of HbA1c Levels in Patients With TB-DM And TB-non DM*. MKB. 51(3):141–6. https://doi.org/10.15395/mkb.v51n3.1753.

61. V. Mahishale, S.Avuthu, Bhagyashri Patil et al. *Effect of Poor Glycemic Control in Newly Diagnosed Patients with Smear-Positive Pulmonary Tuberculosis and Type-2 Diabetes Mellitus.* Iran J Med Sci. 2017 Mar; 42(2): 144–151. PMCID: PMC5366362. PMID: 28360440

62. Tripti Pe, Sophie H, Wilbin X et al. *Prevalence of diabetes mellitus amongst hospitalized tuberculosis patients at an Indian tertiary care center: A descriptive analysis*. PLOS ONE. 2018. https://doi.org/10.1371/journal.pone.0200838 July 18, 2018.

63. M.H Workneh, Gunnar A.B, Solomon A.Y . *Diabetes mellitus is associated with increased mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients in South- Eastern Amahra Region, Ethiopia*. Infectious Diseases of Poverty (2016) 5:22. DOI 10.1186/s40249-016-0115-z.

64.   Medea Gegia, Matthew J M, Russell R.K et al. *Tobacco smoking and tuberculosis treatment outcomes: a prospective cohort study in Georgia*. Bull World Health Organ 2015;93:390–399.

    doi: http://dx.doi.org/10.2471/BLT.14.147439

65. Thanmai K, Varun K.V, Ankush M et al. *Diabetes Mellitus in the Middle-Aged and Elderly Population (>45 Years) and Its Association With Pancreatic Cancer: An Updated Review*.2020. Cureus 12(6): e8884. DOI: 10.7759/cureus.8884.

66. Workneh MH, Bjune GA, Yimer SA. *Prevalence and associated factors of tuberculosis and diabetes mellitus comorbidity: a systematic review*. PloS one.

2017; 12(4):e0175925. https://doi.org/10.1371/ journal.pone.0175925 PMID: 28430796.

67. Wahiduddin, W, Pranoto, A, Sudjarwo, S. .*Kendali Glikemik pada Pasien Diabetes Melitus Tipe 2 dengan dan tanpa Tuberkulosis Paru.* Media Kesehatan Masyarakat Indonesia, 15(1), pp. 99-109.

https://journal.unhas.ac.id/index.php/mkmi/article/view/5292

68. N Barreda, M.B. Arriaga, J.G Aliaga et al. *Severe pulmonary radiological manifestations are associated with a distinct biochemical profile in blood of tuberculosis patients with dysglycemia.* BMC.2020.

https://doi.org/10.1186/s12879-020-4843-0.

69. I.D. Kulsum, Erlina Burhan, Rochismandoko. *Faktor yang Mempengaruhi Konversi Sputum BTA Mikroskopik pada Pasien Tuberkulosis Paru Kasus Baru dengan Diabetes Mellitus.* J Respir Indo. 2017; 37: 109-18.

70. A.N Siddiqui, K.U Khayyam, M. Sharma. *Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study.* Hindawi Publishing.2016. http://dx.doi.org/10.1155/2016/7273935.

71. Dana.J Layali, B.Y.M Sinaga, P. Siagian et al. *Hubungan Lesi Tuberkulosis Paru Dengan Diabetes Melitus Terhadap Kadar HbA1c.* Respir Indo Vol. 39 No. 3 Juli 2019. http://www.jurnalrespirologi.org.N.N

72. M.H. Al-Shaer, Hazem Elewa, Yosra Alkabab et al. *Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and*

pulmonary tuberculosis in Qatar. BMC. Infectious Diseases (2018) 18:384. https://doi.org/10.1186/s12879-018-3309-0

73. E. Abinaya, N. Meenakshi, A. Ruckmani et al. *Clinical Evaluation of Efficacy and Safety of Metformin addon Therapy to Standard ATT in Newly Diagnosed Pulmonary Tuberculosis Patients*. Biomedical & Pharmacology Journal, March 2020. Vol. 13(1), p. 299-309. http://dx.doi.org/10.13005/bpj/1889.

74. Li-Kuo Huang, Liang-De Jiang, Yi-Chun Lai et al. *Pulmonary tuberculous cavities in diabetic patients: Glycemic control is still the dominant factor despite the emerging role of metformin. Journal of Chinese Medical Association. (2019) 82: 628-634. doi: 10.1097/JCMA.0000000000000132.*

75. Ratnawati, Dewi Wijaya, A.M Nazaruddin et al. *The relationship between hemoglobin A1C levels and sputum conversion time in indonesian patients with new cases of pulmonary tuberculosis*. J Nat Sc Biol Med 2018;9:217-21. DOI: 10.4103/jnsbm.JNSBM_24_18.

76. Dina Keumala Sari, Juli Yosa Mega, Juliandi Harahap. *Nutrition Status Related to Clinical Improvement in AFB-Positive Pulmonary Tuberculosis Patients in Primary Health Centres in Medan, Indonesia.* J Med Sci. 2019 May 31; 7(10):1621-1627.

77. Tika Dwi Tama, Asri C. Adisasmita, Erlina Burhan. *Body Mass Index and T ime to Sputum Smear Conversion Among Acid-Fast Bacilli (AFB) Positive Pulmonary Tuberculosis Patients at RSUP Persahabatan 2012.* Jurnal Epidemiologi Kesehatan Indonesia Vol. 1, No. 1, November 2016.

78. Suku Sneha. *Malnutrition Related Diabetes Mellitus in Indian Population.* International Journal of Research and Review. Review Article. Vol.7; Issue: 7; 2020. www.ijrrjournal.com. E-ISSN: 2349-9788; P-ISSN: 2454-2237.

79. Sonia Menon, Rodolfo Rossi, Leon Nshimyumukiza et al. *Convergence of a diabetes mellitus, protein energy malnutrition, and TB epidemic: the neglected elderly population.* BMC Infectious Diseases (2016) 16:361. DOI 10.1186/s12879-016-1718-5.

80. Julie Silverman, James Krieger, Meghan Kiefer et al. *The Relationship Between Food Insecurity and Depression, Diabetes Distress and Medication Adherence Among Low-Income Patients with Poorly-Controlled Diabetes*. J Gen Intern Med 30(10):1476–80. 2015. DOI: 10.1007/s11606-015-3351-1.

82. Akadiri Y Jean-Marc Ategbo, Kabirou M et al. *Malnutrition-modulated diabetes mellitus (MMDM): a state of review*. nt. J. Biol. Chem. Sci. 2(2): 230-238, 2008.

83. Gupta KB, Gupta R, Atreja A et al. Tuberculosis and nutrition. Lung India. 2009;26(1):9–16.

84. *Sheba Denisica Nasution. Malnutrisi dan Anemia Pada Penderita Tuberkulosis Paru*. majority. 2015. 4: 8/29.

LAMPIRAN

1. Kode Etik

KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 607/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 5 Oktober 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20090442	No Sponsor Protokol	
Peneliti Utama	**dr. Franciscus A. Wabia**	Sponsor	
Judul Peneliti	PERBANDINGAN KONVERSI SPUTUM BTA PENDERITA TUBERKULOSIS PARU KASUS BARU DAN DIABETES MELITUS YANG DITERAPI DENGAN ANTI DIABETIK ORAL ATAU INSULIN		
No Versi Protokol	**2**	Tanggal Versi	**1 Oktober 2020**
No Versi PSP	**2**	Tanggal Versi	**1 Oktober 2020**
Tempat Penelitian	**RSUP Dr.Wahidin Sudirohusodo dan RS Jejaring, RSUD Labuang Baji, Balai Besar Kesehatan Paru Masyarakat Makassar dan Dinas Kesehatan Kota Makassar (Puskesmas Batua)**		

Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku **5 Oktober 2020** sampai **5 Oktober 2021**	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:
- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan